M. Mass

发表

Magnetic resonance studies of intramuscular interferon β–1a for relapsing multiple sclerosis

Jeanelle Sheeder, C. Granger, R. Herndon, 1998 .

Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis

C. Granger, R. Herndon, R. Kinkel, 1996, Annals of neurology.

Eight-year follow-up study of brain atrophy in patients with MS

J H Simon, G Cutter, R. Rudick, 2002, Neurology.

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. 1997.

R. Kinkel, J. Fischer, R. Rudick, 1997, Neurology.

T cells with encephalitogenic potential from multiple sclerosis patients and Lewis rats fail to induce disease in SCID mice following intracisternal injection

D. Bourdette, A. Vandenbark, M. Mass, 1995, Journal of Neuroimmunology.

Encephalitogenic T lymphocytes develop from SJL/J hematopoietic cells transplanted into severe combined immimodeficient ( SCID) mice

D. Bourdette, R. Whitham, M. Mass, 1995, Journal of Neuroimmunology.

A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis

C. Guttmann, D. Bourdette, J. Bowen, 2005, Multiple sclerosis.

Diminished frequency of interleukin‐10‐secreting, T‐cell receptor peptide‐reactive T cells in multiple sclerosis patients might allow expansion of activated memory T cells bearing the cognate BV gene

D. Bourdette, D. Barnes, A. Vandenbark, 2001, Journal of neuroscience research.

Myelination of axons within cytosine arabinoside treated mouse cerebellar explants by cultured rat oligodendrocytes

R. Herndon, R. Saneto, M. Mass, 1989, Brain Research.

Treatment of relapsing autoimmune encephalomyelitis with T cell receptor Vβ‐specific antibodies when proteolipid protein is the autoantigen

R. Whitham, K. Wegmann, M. Mass, 1996, Journal of neuroscience research.

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis

R. Herndon, R. Rudick, J. Simon, 1998, Neurology.

Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

C. Granger, R. Kinkel, J. Fischer, 1999, Journal of neuroimmunology.

Myelin basic protein-specific T lymphocytes induce chronic relapsing experimental autoimmune encephalomyelitis in lymphocyte-deficient (SCID) mice

D. Bourdette, M. Mass, Richard E. Jones, 1999, Journal of Neuroimmunology.

Randomized controlled trial of atorvastatin in clinically isolated syndrome

A. Cross, A. Bar-Or, E. Rosenberg, 2012, Neurology.

Oral lipoic acid as a treatment for acute optic neuritis: a blinded, placebo controlled randomized trial

D. Bourdette, C. Murchison, V. Yadav, 2017, Multiple sclerosis journal - experimental, translational and clinical.

Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis.

T. Vollmer, G. Francis, W. Sheremata, 1997, Archives of neurology.

Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS

G Cutter, D. Dougherty, D. Miller, 2001, Neurology.

Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled Trial.

M. Goldman, F. Bethoux, A. Applebee, 2015, International journal of MS care.

Therapeutic vaccination with a trivalent T‐cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis

D. Bourdette, A. Vandenbark, H. Offner, 2008, Immunology.

Randomized controlled trial of yoga and exercise in multiple sclerosis

S. Kishiyama, B. Oken, D. Bourdette, 2004, Neurology.

Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis

R. Rudick, G. Cutter, B. Weinstock-Guttman, 2005, Neurology.

The contemporary spectrum of multiple sclerosis misdiagnosis

Gregory F. Wu, B. Weinshenker, A. Cross, 2016, Neurology.

Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients.

G Cutter, R. Rudick, G. Cutter, 2000, Multiple sclerosis.

Sporadic Creutzfeld Jakob Disease in a 33 Year old Male with Prior Cerebral Instrumentation (P06.195)

M. Mass, Keiran K. Tuck, 2013 .

Treatment of multiple sclerosis with T–cell receptor peptides: Results of a double–blind pilot trial

D. Bourdette, A. Vandenbark, H. Offner, 1996, Nature Medicine.

Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials

J. Simon, R. Priore, L. Jacobs, 1998, Multiple sclerosis.

Results of an Ongoing, Open-Label, Safety-Extension Study of Interferon Beta-1a (Avonex) Treatment in Multiple Sclerosis

R. Herndon, E. Waubant, R. Rudick, 1999 .

Eight-year immunogenicity and safety of interferon beta-1a-Avonex®treatment in patients with multiple sclerosis

R. Herndon, R. Rudick, F. Munschauer, 2005, Multiple sclerosis.

Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients

R. Rudick, G. Cutter, E. Fisher, 2005, Multiple sclerosis.

Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients

G Cutter, R. Rudick, G. Cutter, 2000 .

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis

R. P. Kinkel, D. L. Cookfair, R. Herndon, 1997, Neurology.

Cerebrospinal fluid abnormalities in a phase III trial of Avonex® (IFNβ-1a) for relapsing multiple sclerosis 1 Studies supported by the National Multiple Sclerosis Society (grants RG2019, RG2827); the NINDS (NS26321); and Biogen Inc. 1

C. Granger, R. Herndon, R. Kinkel, 1999, Journal of Neuroimmunology.

Factors that predict Health-Related Q uality of Life in patients with relapsing -remitting multiple sclerosis

Deborah M. Miller, R. Rudick, G. Cutter, 2003, Multiple Sclerosis.

Predictors of short-term disease activity following a first clinical demyelinating event: analysis of the CHAMPS placebo groupy

Jeffrey A. Cohen, S. Cole, D. Arnold, 2002, Multiple sclerosis.